Hikma Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hikma Pharmaceuticals plc
Hikma Expands In Canada With Four New Injectables
Hikma has bolstered its generic sterile injectables business in Canada with four new launches.
Hikma Manages To Stay Flat In 2022 Despite Generics Pressures
As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.
Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Custopharm, Inc.
- EIMC United Pharmaceuticals
- Roxane Laboratories, Inc.
- West-Ward Pharmaceuticals Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.